Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mahamaya Lifesciences has informed that the Board of Directors of the Company, through a circular resolution passed on 10th March 2026, has approved the utilisation of the unutilised Initial Public Offer (IPO) proceeds in subsequent fiscal years i.e., up to March 31, 2028, in a phased manner.
The above information is a part of company’s filings submitted to BSE.